Back

Comparative analysis of clinical adverse outcomes in cardiac resynchronization therapy: transvenous lead vs epicardial lead

12 May 2024 (09:00 - 10:20)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - epidemiology, prognosis, outcome 4 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Luisa Pinheiro

Unidade Local de Saude do Alto Ave, Guimaraes (Portugal)

5 More presentations in this session

Presentation thumbnail
Proteomic analysis of potential biomarkers of recent onset dilated cardiomyopathy for prediction of the therapy outcome
Professor R. Pudil (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
The prevalence of cardiotropic viruses among the Polish population with viral heart disease
Professor A. Pawlak (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Differential effect of sex on mortality according to age in heart failure
Associate Professor J. Park (Seongnam, KR)
Abstract Slides Video
Presentation thumbnail
Predicting worsening heart failure events: a novel prediction model - a single centre analysis
Doctor C. Miguel Goncalves (Leiria, PT)
Abstract Slides Video
Presentation thumbnail
Heart failure disparities by sex: a comparative analysis of a real-world population in a regional hospital
Doctor A. Fonseca Vazao (Leiria, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - epidemiology, prognosis, outcome 4

The Event

Event poster

Heart Failure 2024

12 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Assessing the response to cardiac resynchronization therapy in heart failure patients: a comparative analysis between transvenous and epicardial leads.
thumbnail
Congress Presentation
Comparing LV lead performance and procedure-related complications: transvenous vs epicardial leads in cardiac resynchronization therapy
thumbnail
Congress Presentation
Differential outcomes of cardiac resynchronization therapy based on heart failure etiology

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources